Story thread · 2 reports / 2 sources
Celldex's hives drug faces safety questions despite Phase 3 successes
endpts.com · 4h · first report
Celldex said its experimental treatment barzolvolimab hit its primary endpoint in two Phase 3 trials, even as the readout raised safety concerns on two life-threatening cases of allergic reaction following administration of the drug. The ...
The coverage
- Celldex sinks as safety concerns cloud immune drug results
biopharmadive.com · 4h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.